Dedicated breast MRI systems offer significant improvement in performance and diagnostic accuracy.
Dedicated breast MRI systems offer significant improvement in performance and diagnostic accuracy, said researchers in a study published in the October issue of the journal Radiology.
Researchers assessed the sensitivity and specificity of images of 934 patients (347 screening exams and 587 diagnostic exams) from April 2006 to December 2007. The women were between the ages of 25 and 89. The images were taken by Aurora Imaging Technology Inc.’s dedicated 1.5-T breast MR system that used high-spatial-resolution, high-contrast-resolution spiral trajectory acquisitions.
Results showed sensitivity for the dedicated MRI system of 92 percent (92 women out of 100) and specificity of 88.9 percent (741 women out of 834). The negative predictive value for screening cases was 100 percent. The area under the receiver operating characteristics (ROC) curve was 94 percent. The false-positive rate was 93 of 834 (11.2 percent) for all cases, but only 16 of 326 (4.9 percent) for the screening cohort.
“False positive rates from previously reported trials using whole-body breast MRI have typically been between 30 and 50 percent,” study investigator Alan Hollingsworth, MD, said in a release. Hollingsworth is the medical director and a breast surgeon at Mercy Women’s Center at Mercy Health Center.
“These studies have led to criticism of breast MRI for its high false positive rates, resulting in unnecessary biopsies, surgical procedures and anxiety for the patient,” he said. “The dedicated breast MRI system offers a significant improvement in performance. Even with 93 false positives, 25 (27 percent) were high-risk histologies for which excision is often recommended. This kind of performance should provide breast radiologists and surgeons alike a higher level of diagnostic confidence and could have significant impact on the role of breast MRI.”
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.